iSpecimen Inc. (ISPC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
iSpecimen Inc. (ISPC) trades at $2.56 with AI Score 17/100 (Grade F). iSpecimen Inc. operates a marketplace connecting researchers with human biospecimens. Market cap: $355,487, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for ISPC: ISPC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ISPC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ISPC: 1/1 perspectives are bearish.
How is this calculated? →iSpecimen Inc. (ISPC) Healthcare & Pipeline Overview
iSpecimen Inc. provides a technology platform connecting researchers with human biospecimens from a network of healthcare providers. Its iSpecimen Marketplace facilitates the efficient sourcing of biofluids, tissues, and cells, serving the biopharmaceutical, in vitro diagnostic, and government/academic research sectors within the broader healthcare industry.
What Is the Investment Thesis for ISPC?
iSpecimen Inc. presents a unique investment opportunity within the medical research sector, driven by its innovative iSpecimen Marketplace. The platform addresses a critical need in the life sciences industry by streamlining the sourcing of human biospecimens. The company's growth is tied to the increasing demand for personalized medicine and the growing complexity of medical research, which necessitates access to diverse and well-characterized biospecimens. Key value drivers include expansion of the iSpecimen Marketplace network, increased adoption by biopharmaceutical and diagnostic companies, and strategic partnerships with healthcare organizations. However, the company's negative profit margin of -344.0% and small market capitalization pose significant risks. Success hinges on achieving profitability through increased transaction volume and efficient cost management. Continued innovation and adaptation to evolving regulatory requirements are also crucial for long-term sustainability.
Based on FMP financials and quantitative analysis
ISPC Key Highlights
- iSpecimen operates a cloud-based marketplace connecting researchers with biospecimens.
- The company serves biopharmaceutical, in vitro diagnostic, and government/academic institutions.
- iSpecimen's technology streamlines the sourcing of human biofluids, tissues, and cells for research.
- The company's gross margin is 21.6%.
- iSpecimen has a negative profit margin of -344.0%.
Who Are ISPC's Competitors?
ISPC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIVI BioVie Inc. | $2.04 | +4.87% | $15.42M | — |
| HSCS HeartSciences Inc. | $2.71 | -2.69% | $5.88M | — |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ISPC's Key Strengths?
- Proprietary iSpecimen Marketplace platform.
- Extensive network of healthcare provider organizations.
- Specialized expertise in biospecimen sourcing and logistics.
- Cloud-based technology enables efficient specimen searching and procurement.
What Are ISPC's Weaknesses?
- Negative profit margin.
- Small market capitalization.
- Reliance on third-party healthcare organizations for specimen supply.
- Limited brand recognition.
What Could Drive ISPC Stock Higher?
- Potential new partnerships with major research institutions to expand specimen access.
- Increasing demand for biospecimens due to advancements in personalized medicine.
- Expansion of the iSpecimen Marketplace network to include more healthcare providers.
What Are the Key Risks for ISPC?
- Financial-distress signal — its Altman Z-Score of -23.66 sits in the distress zone (elevated bankruptcy risk).
- Competition from other biospecimen providers.
- Changes in regulatory requirements for biospecimen sourcing.
- Negative profit margin and need to achieve profitability.
- Economic downturns that could reduce research funding.
What Are the Growth Opportunities for ISPC?
- Expansion of the iSpecimen Marketplace network: iSpecimen has the opportunity to grow by expanding its network of healthcare provider organizations. Onboarding more hospitals, labs, and biobanks would increase the variety and availability of biospecimens on the platform, attracting more researchers and driving transaction volume. This expansion could be achieved through strategic partnerships, targeted outreach, and incentives for participation. The market for biospecimens is estimated to be worth billions of dollars, providing ample opportunity for growth.
- Increased adoption by biopharmaceutical companies: Biopharmaceutical companies are major consumers of human biospecimens for drug discovery and development. iSpecimen can increase its market share by targeting these companies with tailored solutions and services. This could involve developing specialized workflows for specific research areas, providing dedicated support teams, and offering customized pricing models. The biopharmaceutical industry's investment in research and development continues to grow, creating a strong demand for biospecimens.
- Strategic partnerships with in vitro diagnostic companies: In vitro diagnostic (IVD) companies rely on biospecimens for the development and validation of their diagnostic tests. iSpecimen can forge strategic partnerships with IVD companies to provide them with access to the specimens they need. This could involve providing exclusive access to certain specimen types, collaborating on research projects, and developing joint marketing initiatives. The IVD market is experiencing rapid growth, driven by advancements in personalized medicine and the increasing demand for diagnostic testing.
- Geographic expansion into new markets: iSpecimen can expand its geographic reach by entering new markets outside of the United States. This could involve establishing partnerships with healthcare organizations in other countries, translating the iSpecimen Marketplace into other languages, and adapting its services to meet local regulatory requirements. The global market for biospecimens is large and growing, providing ample opportunity for geographic expansion.
- Leveraging data analytics to improve specimen sourcing: iSpecimen can leverage data analytics to improve the efficiency and effectiveness of its specimen sourcing process. By analyzing data on specimen demand, availability, and pricing, iSpecimen can optimize its marketplace to connect researchers with the specimens they need more quickly and easily. This could involve developing algorithms to predict specimen demand, identifying new sources of specimens, and optimizing pricing strategies. The use of data analytics is becoming increasingly important in the healthcare industry, and iSpecimen can leverage this trend to gain a competitive advantage.
What Opportunities Does ISPC Have?
- Expansion of the iSpecimen Marketplace network.
- Increased adoption by biopharmaceutical companies.
- Strategic partnerships with in vitro diagnostic companies.
- Geographic expansion into new markets.
What Threats Does ISPC Face?
- Competition from other biospecimen providers.
- Changes in regulatory requirements for biospecimen sourcing.
- Economic downturns that could reduce research funding.
- Cybersecurity threats that could compromise the iSpecimen Marketplace platform.
What Are ISPC's Competitive Advantages?
- Proprietary iSpecimen Marketplace platform.
- Extensive network of healthcare provider organizations.
- Specialized expertise in biospecimen sourcing and logistics.
What Does ISPC Do?
iSpecimen Inc., founded in 2009 and headquartered in Woburn, Massachusetts, operates at the intersection of healthcare and research, providing a technology platform that connects life science researchers with the human biospecimens they need. The company's core offering is the iSpecimen Marketplace, a cloud-based platform that allows researchers to search for and procure biofluids, tissues, and living cells from a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations worldwide. This platform streamlines the traditionally complex and time-consuming process of sourcing specimens for research. iSpecimen serves a diverse range of clients, including biopharmaceutical companies, in vitro diagnostic companies, and government and academic institutions, all of whom rely on human biospecimens for their research and development efforts. By providing a centralized and efficient marketplace, iSpecimen aims to accelerate the pace of medical discovery and improve patient outcomes. The company's technology enables scientists to specify their exact needs, including patient demographics, diagnoses, and specimen characteristics, and then connect with suppliers who can fulfill those requirements. This targeted approach ensures that researchers can obtain the specific specimens they need for their studies, while also providing healthcare organizations with a way to monetize their bio specimen assets.
What Products and Services Does ISPC Offer?
- Connect life science researchers with human biospecimens.
- Operate the iSpecimen Marketplace, a cloud-based platform for sourcing biofluids, tissues, and cells.
- Enable researchers to search for specimens and patients across a network of healthcare organizations.
- Serve biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
- Provide access to a wide range of specimen types and patient data.
- Streamline the process of sourcing specimens for research.
How Does ISPC Make Money?
- iSpecimen generates revenue by charging fees for transactions conducted through the iSpecimen Marketplace.
- The company charges researchers for access to specimens and data.
- iSpecimen also generates revenue from healthcare organizations for providing them with a platform to monetize their biospecimen assets.
What Industry Does ISPC Operate In?
iSpecimen Inc. operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in personalized medicine and the increasing complexity of research. The market for human biospecimens is expanding as researchers require more diverse and well-characterized samples. iSpecimen's iSpecimen Marketplace positions it as a facilitator within this ecosystem, connecting researchers with healthcare organizations that possess these valuable resources. Competitors include companies like BIAF, BIVI, BJDX, GLMD, and HSCS, which offer various diagnostic and research tools and services. iSpecimen differentiates itself through its marketplace model, providing a centralized platform for sourcing a wide range of biospecimens.
Who Are ISPC's Key Customers?
- Biopharmaceutical companies conducting drug discovery and development.
- In vitro diagnostic companies developing and validating diagnostic tests.
- Government and academic institutions conducting medical research.
How iSpecimen Inc. Is Valued
iSpecimen Inc. carries a market capitalization of 355K, placing it in the micro-cap category. Relative to its peer group, ISPC's quantitative score of 17/100 is below the peer average of 68/100.
Company Profile
iSpecimen Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Katharyn Field. ISPC has traded publicly since 2021.
F-Score 4/9Financial Health
iSpecimen Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -23.66 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project iSpecimen Inc. revenue of about $37.8M for fiscal 2026, with EPS near $0.00.
ISPC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying activity has increased recently, signaling confidence from management in the company's future.
- Community sentiment has shifted positively, with discussions highlighting the potential of iSpecimen's unique biorepository services.
- Recent partnerships announced in the last month have garnered attention, suggesting growth opportunities and increased market presence.
- Analysts in the social trading community are increasingly optimistic about iSpecimen's role in advancing personalized medicine.
Bear Case
- Some community members express concerns about the company's scalability and whether it can meet growing demand effectively.
- Recent competitive pressures have emerged, with new entrants in the biorepository space potentially impacting market share.
- Discussions around regulatory hurdles have surfaced, raising doubts about the speed of product approvals and market entry.
- Market perception remains cautious due to historical volatility in similar biotech stocks, leading to a bearish sentiment among some traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ISPC Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Jun 17, 2026
-
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jun 3, 2024
ISPC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ISPC.
Price Targets
Wall Street price target analysis for ISPC.
ISPC MoonshotScore
What does this score mean?
The MoonshotScore rates ISPC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest iSpecimen Inc. Analysis
Leadership: Katharyn Field
CEO
Katharyn Field serves as the CEO of iSpecimen Inc., leading a team of 24 employees. Her background includes extensive experience in healthcare and technology, with a focus on driving innovation and growth. Prior to joining iSpecimen, she held leadership positions at various healthcare companies, where she was responsible for developing and implementing strategic initiatives. Her expertise spans areas such as product development, marketing, and sales. She brings a strong understanding of the challenges and opportunities facing the medical research sector.
Track Record: Since assuming the role of CEO, Katharyn Field has focused on expanding the iSpecimen Marketplace network and increasing adoption by biopharmaceutical and diagnostic companies. She has also overseen the development of new features and functionalities for the platform, aimed at improving the user experience and streamlining the specimen sourcing process. Under her leadership, iSpecimen has continued to innovate and adapt to the evolving needs of the medical research community.
What Investors Ask About iSpecimen Inc. (ISPC) — Healthcare
What does iSpecimen Inc. do?
iSpecimen Inc. operates a technology platform, the iSpecimen Marketplace, that connects life science researchers with human biospecimens. The company facilitates the sourcing of biofluids, tissues, and cells from a network of healthcare provider organizations worldwide. This platform enables researchers to efficiently search for and procure the specific specimens they need for their research, accelerating the pace of medical discovery. iSpecimen serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions, providing a centralized and streamlined solution for biospecimen procurement.
What are the main risks for ISPC?
iSpecimen Inc. faces several risks, including competition from other biospecimen providers, changes in regulatory requirements for biospecimen sourcing, and the need to achieve profitability. The company's negative profit margin poses a significant challenge, requiring increased transaction volume and efficient cost management. Economic downturns could also reduce research funding, impacting demand for biospecimens. Cybersecurity threats could compromise the iSpecimen Marketplace platform, disrupting operations and damaging the company's reputation. Navigating these risks is crucial for iSpecimen's long-term sustainability and success.
How does iSpecimen Inc. ensure the quality and ethical sourcing of biospecimens?
iSpecimen Inc. addresses quality and ethical concerns through rigorous vetting processes for healthcare provider organizations within its network. The company ensures compliance with relevant regulations and ethical guidelines, including informed consent and patient privacy. The iSpecimen Marketplace platform also provides detailed information about specimen characteristics and sourcing procedures, allowing researchers to make informed decisions. Continuous monitoring and auditing of its network help maintain high standards for specimen quality and ethical sourcing, building trust and confidence among researchers and healthcare providers.
What revenue streams does iSpecimen Inc. have in healthcare?
iSpecimen Inc.'s primary revenue stream is derived from transaction fees charged to researchers for accessing biospecimens and data through the iSpecimen Marketplace. The company also generates revenue from healthcare organizations by providing them with a platform to monetize their biospecimen assets. Revenue is influenced by factors such as the volume of transactions, the types of specimens sourced, and the pricing of specimens. Strategic partnerships with biopharmaceutical and diagnostic companies can also contribute to revenue growth. Diversifying revenue streams and expanding its customer base are key priorities for iSpecimen.
What are the key factors to evaluate for ISPC?
iSpecimen Inc. (ISPC) holds an AI score of 17/100 (low). Not financial advice.
How frequently does ISPC data refresh on this page?
ISPC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ISPC's recent stock price performance?
iSpecimen Inc. (ISPC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary iSpecimen Marketplace platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ISPC overvalued or undervalued right now?
Valuing iSpecimen Inc. (ISPC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for ISPC, limiting the depth of financial analysis.
- Small market capitalization and negative profit margin indicate higher risk.